Trial Profile

Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In Hematologic Malignant Patients Under intensive Chemotherapy (CIMON)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MaaT 033 (Primary)
Indications Acute myeloid leukaemia; Dysbiosis; Haematological malignancies; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms CIMON
Sponsors MaaT Pharma

27 Jul 2023 According to a MaaT Pharma media release, results from this trial were presented during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023) in April.
11 Apr 2023 According to a MaaT Pharma media release, results from this trial will be presented during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023).
11 Apr 2023 Results presented in the MaaT Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com